Literature
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)
Signal observed that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduced heart failure hospitalization by 22% and cardiovascular death by 18% in a meta-analysis of over 14,000 adult patients with chronic kidney disease. Evidence suggests the cardiovascular benefits were consistent across different kidney disease etiologies and stages, though hyperkalaemia occurred more frequently with treatment. Worth noting this represents adult chronic kidney disease populations rather than pediatric congenital heart disease patients.
Bayer.
Relevance: Relates to heart failure management which is relevant to practice profile, but focuses on adult CKD populations rather than pediatric congenital cardiac conditions